 MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 PRNewswire -- Alterity Therapeutics ASX: ATH, NASDAQ: ATHE Alterity or the Company, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Companys Biomarkers of progression in Multiple System Atrophy bioMUSE study at the International Parkinson and Movement Disorder Society Virtual Congress 2021 being held September 17-22, 2021. 